Chapter 1. Neuro-Oncology Diagnostics Market – Scope & Methodology
1.1 Market Segmentation
1.2 Scope, Assumptions & Limitations
1.3 Research Methodology
1.4 Primary Sources
1.5 Secondary Sources
Chapter 2. Neuro-Oncology Diagnostics Market – Executive Summary
2.1 Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2 Key Trends & Insights
2.2.1 Demand Side
2.2.2 Supply Side
2.3 Attractive Investment Propositions
2.4 COVID-19 Impact Analysis
Chapter 3. Neuro-Oncology Diagnostics Market – Competition Scenario
3.1 Market Share Analysis & Company Benchmarking
3.2 Competitive Strategy & Development Scenario
3.3 Competitive Pricing Analysis
3.4 Supplier-Distributor Analysis
Chapter 4. Neuro-Oncology Diagnostics Market Entry Scenario
4.1 Regulatory Scenario
4.2 Case Studies – Key Start-ups
4.3 Customer Analysis
4.4 PESTLE Analysis
4.5 Porters Five Force Model
4.5.1 Bargaining Power of Suppliers
4.5.2 Bargaining Powers of Customers
4.5.3 Threat of New Entrants
4.5.4 Rivalry among Existing Players
4.5.5 Threat of Substitutes
Chapter 5. Neuro-Oncology Diagnostics Market – Landscape
5.1 Value Chain Analysis – Key Stakeholders Impact Analysis
5.2 Market Drivers
5.3 Market Restraints/Challenges
5.4 Market Opportunities
Chapter 6. Neuro-Oncology Diagnostics Market – By Test Type
6.1 Introduction/Key Findings
6.2 Imaging Tests
6.3 Biopsy
6.4 Lumbar Puncture
6.5 Molecular Testing
6.6 Electroencephalography (EEG)
6.7 Platform and Services
6.8 Others
6.9 Y-O-Y Growth trend Analysis By Test Type
6.10 Absolute $ Opportunity Analysis By Test Type, 2023-2030
Chapter 7. Neuro-Oncology Diagnostics Market – By Cancer Type
7.1 Introduction/Key Findings
7.2 Acoustic Neuroma
7.3 Astrocytomas
7.4 Glioblastoma Multiforme
7.5 Meningiomas
7.6 Oligodendroglioma
7.7 Others
7.8 Y-O-Y Growth trend Analysis By Cancer Type
7.9 Absolute $ Opportunity Analysis By Cancer Type, 2024-2030
Chapter 8. Neuro-Oncology Diagnostics Market – By Age Group
8.1 Introduction/Key Findings
8.2 0-15
8.3 15-39
8.4 40-65
8.5 65 and above
8.6 Y-O-Y Growth trend Analysis By Age Group
8.7 Absolute $ Opportunity Analysis By Age Group, 2023-2030
Chapter 9. Neuro-Oncology Diagnostics Market – By End-User
9.1 Introduction/Key Findings
9.2 Hospitals
9.3 Specialty clinics
9.4 Diagnostic centers and research institutes
9.5 Ambulatory surgical centers
9.6 Others
9.7 Y-O-Y Growth trend Analysis End-User
9.8 Absolute $ Opportunity Analysis End-User, 2024-2030
Chapter 10. Neuro-Oncology Diagnostics Market , By Geography – Market Size, Forecast, Trends & Insights
10.1 North America
10.1.1 By Country
10.1.1.1 U.S.A.
10.1.1.2 Canada
10.1.1.3 Mexico
10.1.2 By Test Type
10.1.2.1 By Cancer Type
10.1.3 By Age Group
10.1.4 Countries & Segments - Market Attractiveness Analysis
10.2 Europe
10.2.1 By Country
10.2.1.1 U.K
10.2.1.2 Germany
10.2.1.3 France
10.2.1.4 Italy
10.2.1.5 Spain
10.2.1.6 Rest of Europe
10.2.2 By Test Type
10.2.3 By Cancer Type
10.2.4 By Age Group
10.2.5 By End-User
10.2.6 Countries & Segments - Market Attractiveness Analysis
10.3 Asia Pacific
10.3.1 By Country
10.3.1.1 China
10.3.1.2 Japan
10.3.1.3 South Korea
10.3.1.4 India
10.3.1.5 Australia & New Zealand
10.3.1.6 Rest of Asia-Pacific
10.3.2 By Test Type
10.3.3 By Cancer Type
10.3.4 By Age Group
10.3.5 By End-User
10.3.6 Countries & Segments - Market Attractiveness Analysis
10.4 South America
10.4.1 By Country
10.4.1.1 Brazil
10.4.1.2 Argentina
10.4.1.3 Colombia
10.4.1.4 Chile
10.4.1.5 Rest of South America
10.4.2 By Test Type
10.4.3 By Cancer Type
10.4.4 By Age Group
10.4.5 By End-User
10.4.6 Countries & Segments - Market Attractiveness Analysis
10.5 Middle East & Africa
10.5.1 By Country
10.5.1.1 United Arab Emirates (UAE)
10.5.1.2 Saudi Arabia
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 South Africa
10.5.1.6 Nigeria
10.5.1.7 Kenya
10.5.1.8 Egypt
10.5.1.9 Rest of MEA
10.5.2 By Test Type
10.5.3 By Cancer Type
10.5.4 By Age Group
10.5.5 By End-User
10.5.6 Countries & Segments - Market Attractiveness Analysis
Chapter 11. Neuro-Oncology Diagnostics Market – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1 NIHON KOHDEN CORPORATION.
11.2 FUJIFILM Holdings Corporation
11.3 GE HealthCare
11.4 Koninklijke Philips N.V.
11.5 BD
11.6 Siemens Healthcare GmbH
11.7 Others
2850
5250
4500
1800
Frequently Asked Questions
Global Neuro-Oncology Diagnostics Market was valued at USD 1.80 Billion and is projected to reach a market size of USD 3.21 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 8.6%.
The worldwide global neuro-oncology diagnostics market growth is estimated to grow by around 8.6% from 2023 to 2030.
The Global NeuroOncology Diagnostics Market is segmented by Test Type, by Cancer Type, by Age Group, and by End User.
The market is expected to see growth through rising awareness of early diagnosis of brain cancer, advancements in technologies like improved imaging techniques, along innovation in drug delivery to brain cancer increasing the size of the market.
The COVID-19 pandemic disrupted the supply chain of the diagnostic market reducing the overall market size in 2020. However, the market is increasing as people have to get diagnosed after the lockdown scenario.